Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report

Treatment options as second-line therapy for advanced ureteral carcinoma are limited, and patients experiencing recurrence after first-line cisplatin-based chemotherapy have a poor prognosis. Recently, the programmed death-1 (PD-1) inhibitor pembrolizumab provided a better survival benefit with a co...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikarashi, Daiki, Kitano, Shigehisa, Ishida, Kazuyuki, Nakatsura, Tetsuya, Shimodate, Hitoshi, Tsuyukubo, Takashi, Tamura, Daichi, Kato, Renpei, Sugai, Tamotsu, Obara, Wataru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541700/
https://www.ncbi.nlm.nih.gov/pubmed/33072593
http://dx.doi.org/10.3389/fonc.2020.564714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541700/
https://www.ncbi.nlm.nih.gov/pubmed/33072593
http://dx.doi.org/10.3389/fonc.2020.564714

Ejemplares similares